Vanda Pharmaceuticals Inc. (VNDA): Results of Operations and Financial Condition
Vanda Pharmaceuticals Inc. (VNDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 vnda8-k852026exhibit991.htm EX-99.1 Document Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results • Fanapt ® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31% • Full-year 2026 total revenue guidance o
How this was made
The 30-second read
Why it matters
Traders can update VNDA’s near-term expectations using the new full-year revenue guidance range, cash runway statement through at least end of 2027, and the dated FDA PDUFA target for Quimilza (Dec 12, 2026).
Market read
Primary disclosure of guidance, cash runway, and a fixed FDA decision date can drive repricing ahead of late-2026 catalysts.
What to watch
The 8-K notes revenue timing shifts for HETLIOZ orders shipped late June but recognized in Q3, which can create quarter-to-quarter noise in reported product sales.
Background
This is Vanda’s SEC Form 8-K (Item 2.02) reporting Q2 2026 financial and operational results, plus regulatory and late-stage clinical milestones.
Ticker impact
Vanda reported Q2 2026 results, including Fanapt sales up 23% and full-year 2026 revenue guidance of $240-$290 million.
Near-term bias higher on guidance and FDA milestone visibility, with volatility around the Dec 12, 2026 PDUFA for Quimilza.
The filing is a primary disclosure with specific guidance ($240-$290M), cash balance ($170.0M as of June 30, 2026), and a dated FDA action target (Dec 12, 2026) plus an FDA approval (BYSANTI) and commercial launch updates (NEREUS).
Market effects
Adds incremental datapoints on commercial traction in CNS and antiemetic/rare-disease launches, relevant to small-cap pharma sentiment.
Japan orphan designation for Quimilza is a supportive international regulatory signal, though not a US catalyst by itself.
FDA review progress and a fixed PDUFA date can influence broader biotech risk appetite for similar-stage programs.
Counterpoint
Fanapt growth is offset by steep declines in HETLIOZ, and the company’s cash decreased sharply in Q2, so the runway depends on execution and launch timing.
Key entities
- companyVanda Pharmaceuticals Inc.
Nasdaq-listed biopharma reporting Q2 2026 results, revenue guidance, cash position, and pipeline/regulatory milestones.
- productFanapt (iloperidone)
Q2 2026 net product sales rose 23% to $36.0 million, with prescription growth highlighted.
- productBYSANTI (milsaperidone)
FDA approved in Q1 2026 for bipolar I disorder and schizophrenia; launch expected in second half of 2026.
- productQuimilza (imsidolimab)
BLA for GPP under FDA review with a PDUFA target action date of Dec 12, 2026.
- productNEREUS (tradipitant)
Commercially available in Q2 2026; Q2 net product sales were $1.0 million and launch via web portal began in Q2.
